Merck Stresses Overall Survival In Keytruda/Chemo '189 Trial Revamp
Merck is changing the statistical analysis of combination study in first-line lung cancer to include dual endpoints of progression-free-survival and overall survival, and has withdrawn a filing for the combination in Europe based on mid-stage data.
You may also be interested in...
Success of Keytruda/chemo combo in KEYNOTE-189 first-line metastatic lung cancer study restores Merck's leadership in immuno-oncology and may drive more use, though doctors are still looking to see more data, especially for PD-L1 subgroups.
Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.
The EMA’s scientific committee, the CHMP, has given the green light to new treatments for multiple sclerosis, eosinophilic esophagitis, CMV, hemophilia A, and vaginal atrophy, as well as the EU’s first biosimilar version of Roche’s Avastin. The committee upheld two earlier negative opinions, and two products have been withdrawn from the assessment process.